Skip to main
LYEL

Lyell Immunopharma (LYEL) Stock Forecast & Price Target

Lyell Immunopharma (LYEL) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lyell Immunopharma Inc. has demonstrated a solid financial position with cash, cash equivalents, and marketable securities totaling $320 million, an increase from $297 million in the previous quarter, highlighting effective capital management supported by a recent private placement. The company's product pipeline includes promising candidates such as LYL797, LYL119, and LYL845, showcasing significant potential for expanding treatment options in the solid tumor market through innovative T-cell reprogramming technologies. Additionally, the strong performance of Ronde-cel in the CD19/CD20 CAR-Trace and positive feedback regarding the LYL273 dataset reinforces confidence in the company's ability to capture a leading position in the competitive landscape of cell therapies.

Bears say

Lyell Immunopharma's recent financial report indicates a decline in research and development expenses, dropping to $28.2 million in the third quarter of 2025 from $34.9 million in the previous quarter, highlighting potential concerns about the company’s investment in its development pipeline. The company faces significant risks, including challenges in growing its market share in CAR-T therapies, potential decreases in treatment efficacy, and safety issues that could alter the therapeutic landscape for its candidates. Additionally, the lack of definitive evidence regarding the durability of its key candidate, LYL273, raises concerns about its competitive viability without demonstrable improvements in patient outcomes and toxicity management.

Lyell Immunopharma (LYEL) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lyell Immunopharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lyell Immunopharma (LYEL) Forecast

Analysts have given Lyell Immunopharma (LYEL) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Lyell Immunopharma (LYEL) has a Strong Buy consensus rating as of Dec 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lyell Immunopharma (LYEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.